Fig. 2.

Model external validation using PK data from study ZONDA. Visual prediction checks, grouped by regimen and body weight quantile. Shaded area represents the 90% PI of model-predicted PK exposure. Gray points indicate observed serum concentrations of benralizumab in ZONDA, and blue boxes indicate the observed medians. @4W + 4W + Q8W every 4 weeks for the first three doses, followed by every 8 weeks, Conc. concentration, PI prediction interval, PK pharmacokinetic, Q4W every 4 weeks, SC subcutaneous